Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of TAH3311 (Apixaban ODF) vs. ELIQUIS® in Healthy Volunteers
NCT06689436Phase 2Completed
- Sponsor
- TAHO Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of apixaban in thromboembolism, Atrial fibrillation (AFib), deep vein thrombosis (DVT), pulmonary embolism (PE), sponsored by TAHO Pharmaceuticals. Started Nov 2024; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolismAtrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT06689436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689436.